Calls for papers
-
Aerosol research instrument company Inhalation Sciences (ISAB) has announced the formation of a new scientific advisory board, which will begin meeting on June 1, 2021 to discuss how the company’s PreciseInhale laboratory aerosol dosing system can be… Read more . . .
-
Innoviva is buying back GlaxoSmithKline’s entire stake in the company, a total of 32 million shares (~ 32% of company). Innoviva (formerly Theravance, Inc.), was spun off from Theravance in 2013 to manage the royalties… Read more . . .
-
Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) has signed a knowledge transfer partnership (KTP) with Loughborough University for the development of lower GWP MDI propellants, the company announced. Kindeva says that it “will leverage… Read more . . .
-
Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3… Read more . . .
-
Aerovate Therapeutics has announced that former Proteon Therapeutics President and CEO Timothy Noyes has been named CEO and elected to the company’s board of directors. Noyes was most recently CEO of Arcuate Therapeutics, and he… Read more . . .
-
Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone’s etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing… Read more . . .
-
While RDD 2021, like RDD 2020, was moved online due to the COVID-19 pandemic, the format for this year’s meeting differed from last year’s in that it included live content in addition to prerecorded presentations.… Read more . . .
-
MDI propellant maker Koura has announced the launch of HFA-152a development and filling services at the company’s facilities in Chester, UK. Koura (formerly Mexichem) first announced the possibility of using 152a as a low global warming… Read more . . .
-
Seelos Therapeutics said that the first part of a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder (MDD) demonstrated… Read more . . .
-
Swiss start-up Akroswiss has announced that it raised “several million Swiss Franc” for development of the company’s midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland